Interleukin oprelvekin

Thrombopoietic factors (no recombinant TPO product in clinical use at this time IL-11 [recombinant product oprelvekin] has marketing approval) stimulate the production of megakaryocyte precursors, megakaryocytes, and platelets [8]. Interleukin-11 has many effects on multiple tissues, and can interact with IL-3, TPO, and SCF. AMG 531, a recombinant peptibody in that binds to the thrombopoetin receptor Mpl and stimulates the production of platelets, is in phase 1 and 2 studies and has been shown to safely increase platelet counts in patients with immune thrombocytopenic purpura [9]. 

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. 

In the reported error, a physieian used the abbreviation IL-ll when ordering oprelvekin for a patient. Unfortimately, the order was misinterpreted to be interleukin-2 (i.e., the number eleven was pereeived to be the Roman numeral two). Five or more health eare professionals, ineluding pharmacists and nurses, mistook the order to be aldesleukin. The error was not detected for four days, until it was noted that the inventory of aldesleukin was nearly depleted. 

Interleukin-11 (IL-11, oprelvekin) Thrombocytopenia Patients with nonmyeloid malignancies who receive myelosuppressive cancer chemotherapy... 

Interleukin-11 is a 65-85 kDa protein produced by fibroblasts and stromal cells in the bone marrow. Oprelvekin, the recombinant form of IL-11 approved for clinical use (Table 33-4), is produced by expression in Escherichia coli. The half-life of IL-11 is 7-8 hours when the drug is injected subcutaneously. 

Parenteral (Iron dextran) (InFeD, DexFerrum) 50 mg elemental iron/mL Parenteral (Sodium ferric gluconate complex) (Ferrlecit) 12.5 mg elemental iron/mL Parenteral (Iron sucrose)(Venofer) 20 mg elemental iron/mL Oprelvekin (interleukin-11) (Neumega)... 

Cantor SB, Elting LS, Hudson DV, et al. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 2003 97 3099-3106. 

USA oprelvekin protein Neumega Recombinant human interleukin-11 including residues 2-178, human clone pXM/IL-11, lacking original N-terminal Pro, expressed in E. coli Thrombo- cytopenia... 

Oprelvekin is an interleukin. Interleukin 11 (lL-11) is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation, resulting in increased platelet production. It prevents severe thrombocytopenia and reduces the need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies. 

Recombinant human interleukin-11 oprelvekin (neumega) is a bacteiially derived, 19 kDa polypeptide that lacks the amino terminal Pro residue and is not glycosylated. The recombinant protein has a 7-hour after subcutaneous injection. In normal subjects, daily administration of oprelvekin leads to a thrombopoietic response in 5-9 days. 

C. Megakaryocyte Growth Factors Oprelvekin (interleukin-11, lL-11) and thrombopoietiii... 

Oprelvekin (interleukin Wyeth Human Cell Line... 

Oprelvekin interleukin 1 1 (Neumega) 19 6.9 SC (>0.8) Thrombocytopenia caused by myelosuppressive chemotherapy... 

---